A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE) - Trial NCT06333483
Access comprehensive clinical trial information for NCT06333483 through Pure Global AI's free database. This Phase 1 trial is sponsored by Autolus Limited and is currently Recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Autolus Limited
Timeline & Enrollment
Phase 1
Feb 02, 2024
Oct 01, 2025
Primary Outcome
Dose limiting toxicities,Adverse events
Summary
This is a Phase I study of obecabtagene autoleucel (obe-cel), autologous T cells engineered
 with a chimeric antigen receptor (CAR) targeting CD19, to establish the tolerability, safety,
 preliminary efficacy, and pharmacokinetics of obe-cel in patients with severe, refractory
 SLE.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06333483
Non-Device Trial